Related Experiment Videos
An Abstract Provides "seAFOod" for Thought
Andrea DeCensi1, Andreas Gescher2
1Ospedali Galliera, Genoa, Italy.
Cancer Prevention Research (Philadelphia, Pa.)
|February 1, 2019
Summary
Aspirin and eicosapentaenoic acid (EPA) show potential in preventing colorectal adenomas after resection, despite the seAFOod trial
Area of Science:
- Gastroenterology
- Oncology
- Pharmacology
Background:
- Colorectal adenomas are precursors to colorectal cancer.
- Chemoprevention strategies are crucial for reducing adenoma recurrence.
- The seAFOod trial investigated aspirin and eicosapentaenoic acid (EPA) for adenoma prevention.
Purpose of the Study:
- To evaluate the chemopreventive efficacy of aspirin and EPA in patients with colorectal adenomas.
- To highlight the importance of reporting secondary endpoints in clinical trial abstracts.
Main Methods:
- Patients with colorectal adenomas underwent resection.
- Post-resection treatment involved aspirin and/or eicosapentaenoic acid (EPA).
- Adenoma detection rate and adenoma number were assessed as endpoints.
Main Results:
- The primary endpoint, adenoma detection rate, was negative.
- Significant reductions in adenoma number were observed, suggesting chemopreventive effects of both aspirin and EPA.
- Secondary endpoint findings indicating efficacy were not highlighted in the original abstract.
Conclusions:
- Aspirin and EPA demonstrate potential chemopreventive efficacy against colorectal adenomas.
- Reporting secondary findings in abstracts is vital for comprehensive scientific communication.
- Further research into these agents for colorectal cancer prevention is warranted.